Therapies for neovascular age-related macular degeneration: Current approaches and pharmacologic agents in development

Mostafa Hanout, Daniel Ferraz, Mehreen Ansari, Natasha Maqsood, Saleema Kherani, Yasir J. Sepah, Nithya Rajagopalan, Mohamed Ibrahim, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.

Original languageEnglish (US)
Article number830837
JournalBioMed research international
Volume2013
DOIs
StatePublished - Dec 16 2013

Fingerprint

Macular Degeneration
Vascular Endothelial Growth Factor A
Ophthalmology
Photodynamic therapy
Lasers
Therapeutics
Retinal Diseases
Retinal Vessels
Light Coagulation
Photochemotherapy
Laser Therapy
Blindness
Vascular Diseases
Research Personnel
Clinical Trials
Research
aflibercept
Ranibizumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Hanout, M., Ferraz, D., Ansari, M., Maqsood, N., Kherani, S., Sepah, Y. J., ... Nguyen, Q. D. (2013). Therapies for neovascular age-related macular degeneration: Current approaches and pharmacologic agents in development. BioMed research international, 2013, [830837]. https://doi.org/10.1155/2013/830837

Therapies for neovascular age-related macular degeneration : Current approaches and pharmacologic agents in development. / Hanout, Mostafa; Ferraz, Daniel; Ansari, Mehreen; Maqsood, Natasha; Kherani, Saleema; Sepah, Yasir J.; Rajagopalan, Nithya; Ibrahim, Mohamed; Do, Diana V.; Nguyen, Quan Dong.

In: BioMed research international, Vol. 2013, 830837, 16.12.2013.

Research output: Contribution to journalReview article

Hanout, M, Ferraz, D, Ansari, M, Maqsood, N, Kherani, S, Sepah, YJ, Rajagopalan, N, Ibrahim, M, Do, DV & Nguyen, QD 2013, 'Therapies for neovascular age-related macular degeneration: Current approaches and pharmacologic agents in development', BioMed research international, vol. 2013, 830837. https://doi.org/10.1155/2013/830837
Hanout, Mostafa ; Ferraz, Daniel ; Ansari, Mehreen ; Maqsood, Natasha ; Kherani, Saleema ; Sepah, Yasir J. ; Rajagopalan, Nithya ; Ibrahim, Mohamed ; Do, Diana V. ; Nguyen, Quan Dong. / Therapies for neovascular age-related macular degeneration : Current approaches and pharmacologic agents in development. In: BioMed research international. 2013 ; Vol. 2013.
@article{61c917827771403da95187be581a1cc6,
title = "Therapies for neovascular age-related macular degeneration: Current approaches and pharmacologic agents in development",
abstract = "As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.",
author = "Mostafa Hanout and Daniel Ferraz and Mehreen Ansari and Natasha Maqsood and Saleema Kherani and Sepah, {Yasir J.} and Nithya Rajagopalan and Mohamed Ibrahim and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2013",
month = "12",
day = "16",
doi = "10.1155/2013/830837",
language = "English (US)",
volume = "2013",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Therapies for neovascular age-related macular degeneration

T2 - Current approaches and pharmacologic agents in development

AU - Hanout, Mostafa

AU - Ferraz, Daniel

AU - Ansari, Mehreen

AU - Maqsood, Natasha

AU - Kherani, Saleema

AU - Sepah, Yasir J.

AU - Rajagopalan, Nithya

AU - Ibrahim, Mohamed

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2013/12/16

Y1 - 2013/12/16

N2 - As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.

AB - As one of the leading causes of blindness, age-related macular degeneration (AMD) has remained at the epicenter of clinical research in ophthalmology. During the past decade, focus of researchers has ranged from understanding the role of vascular endothelial growth factor (VEGF) in the angiogenic cascades to developing new therapies for retinal vascular diseases. Anti-VEGF agents such as ranibizumab and aflibercept are becoming increasingly well-established therapies and have replaced earlier approaches such as laser photocoagulation or photodynamic therapy. Many other new therapeutic agents, which are in the early phase clinical trials, have shown promising results. The purpose of this paper is to briefly review the available treatment modalities for neovascular AMD and then focus on promising new therapies that are currently in various stages of development.

UR - http://www.scopus.com/inward/record.url?scp=84890041542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890041542&partnerID=8YFLogxK

U2 - 10.1155/2013/830837

DO - 10.1155/2013/830837

M3 - Review article

C2 - 24319688

AN - SCOPUS:84890041542

VL - 2013

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 830837

ER -